Australia's Imricor rises on seeking FDA nod for product expansion in U.S.
08/04/2026 06:58
** Shares of medical device developer Imricor IMR.AX rise 5.2% to A$1.935, set for best day since March 25 ** Co submits its NorthStar mapping system - an MRI-linked system - to the U.S. Food and Drug Administration for pediatric label expansion ** "The submission to expand NorthStar to include use with pediatric patients represents another important step in the company’s U.S. commercialization strategy" - Co ** Stock up 26.5% YTD (Reporting by Jasmeen Ara Shaikh in Bengaluru) ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))
Recent news on Imricor Medical Systems
See all newsBrief: Imricor Medical Systems Says FDA Completes Review Of Imricor's Third PMA Module
Brief: Imricor Medical Systems Says FDA Accepts Imricor Pma Manufacturing Module
Brief: Imricor Medical Systems Says Anticipated FDA Clearances Of Additional Capital Equipment Expected To Broaden Product Offering Available To U.S. Customers
Imricor Medical Systems hits 3-month high on securing first US hospital customer
Brief: Imricor Medical Systems, Receives FDA 510(K) Clearance For Northstar Pediatric Label Expansion